It was determined that NCALD mRNA was down-regulated in the group with poor prognosis, having advanced stage and poorly differentiated tumors which implied NCALD a prognostic biomarker specific to these ovarian cancer patients [22]. This evidence concerns the gene NCALD and ovarian cancer.